Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Post by Sarb99on Aug 30, 2020 12:14am
922 Views
Post# 31476260

Questcap diverse approach going to pay off end of the Day

Questcap diverse approach going to pay off end of the Day
  • Rather than developing QuestCap own test kits, they form a partnership. Rather than asking labs to sell QuestCap testing kits, they opened their own covid-19 testing centres. QuestCap does not need to buy any building or invest on lab equipment or accessories. Buy as many testing kits as the needs and can sell. Setup mobile testing centres in the pharmacy, schools, Shopping centres, stadiums, or any other place where they can sell. If one place does not get needed crowd, then move somewhere else, place with demand.
 
  • If Abbott Saliva test are cheap, no problem, those tests should be done in a lab according to FDA approval. Start offering lab service for Abbott test. Then charge $25-$35 for lab service to offer Abbott $5 test. QuestCap still make same amount of money. QuestCap does not lose anything, start offering all kind of covid-19 testing. Lyher antibody, Abbott $5 test, Antigen test and take a cut. If they can sell $4 test in Columbia that mean they can compete with Abbott or anyone else.



  • Spectral has already received Institutional Review Board (IRB) approval for the clinical study and the principal investigator for the first phase 1 clinical study has been initiated. Once Spectral receives approval to treat under the PIND application it will begin enrolment for the human clinical study immediately.


  • Amino Therapeutics is currently focused on developing biologic therapeutics for COVID-19. Amino’s research targets small molecule drug candidates and targeted drug delivery systems to transport biologics into the cytosol.
 
  • QuestCap invested in Glenco Medical Corp for long term revenue. QuestCap invested for 28% interest in Columbian Medical clinical, short term as they are busy doing covid-19 testing and long-term planning to open 3 more medical service centres.  

<< Previous
Bullboard Posts
Next >>